AT
KYMR icon

Avalon Trust’s Kymera Therapeutics KYMR Stock Holding History

Avalon Trust’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-500
Closed -$12.7K – 343
2023
Q4 		$12.7K Hold
500
– – ﹤0.01% 287
2023
Q3 		$6.95K Hold
500
– – ﹤0.01% 274
2023
Q2 		$11.5K Hold
500
– – ﹤0.01% 271
2023
Q1 		$14.8K Buy
+500
New +$16.1K ﹤0.01% 245

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Avalon Trust's KYMR Position: Q1 2024 in Review

Avalon Trust sold out of Kymera Therapeutics (KYMR) in Q1 2024, closing a stake of 500 shares — an estimated $12.7K sold.

Avalon Trust first reported a position in KYMR in Q1 2023 and held it in 4 quarters. The position peaked at $14.8K in Q1 2023. 164 funds tracked by Wall St. Rank hold KYMR as of Q1 2024.

  • Avalon Trust reported no remaining Kymera Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Avalon Trust sold 500 Kymera Therapeutics shares in Q1 2024, an estimated $12.7K.
  • Avalon Trust first reported a position in Kymera Therapeutics in Q1 2023 and held it in 4 quarters.
  • Avalon Trust's Kymera Therapeutics position peaked at $14.8K in Q1 2023.
  • 164 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2024.

Based on Avalon Trust's 13F filing for Q1 2024, filed 7 May 2024.